Current Progress in CAR-T Cell Therapy for Hematological Malignancies

Han, Donglei; Xu, Zenghui; Zhuang, Yuan; Ye, Zhenlong; Qian, Qijun

doi:10.7150/jca.48976



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2021; 12(2):326-334. doi:10.7150/jca.48976 This issue Cite

Review

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

Donglei Han^1*, Zenghui Xu^1,2,3*, Yuan Zhuang³, Zhenlong Ye^1,2,3✉, Qijun Qian^1,2,3✉

1. Henan Cell Therapy Group Co. LTD, Zhengzhou, Henan, China.
2. Shanghai University Mengchao Cancer Hospital, Shanghai, China.
3. Shanghai Baize Medical Laboratory, Shanghai, China.
*These authors contributed equally to this work.

Citation:

Han D, Xu Z, Zhuang Y, Ye Z, Qian Q. Current Progress in CAR-T Cell Therapy for Hematological Malignancies. J Cancer 2021; 12(2):326-334. doi:10.7150/jca.48976. https://www.jcancer.org/v12p0326.htm

Other styles

Abstract

Immunotherapies, such as monoclonal antibody therapy and checkpoint inhibitor therapy, have shown inspiring clinical effects for the treatment of cancer. Chimeric antigen receptor T (CAR-T) cells therapy was an efficacious therapeutic approach treating hematological malignancies and encouraging results have been achieved. Three kinds of CAR-T cell therapies, Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), were approved for clinical application in 2017 and Tecartus (brexucabtagene autoleucel) was approved in 2020. Despite some progress have been made in treating multiple hematologic tumors, threats still remain for the application of CAR-T cell therapy considering its toxicities and gaps in knowledge. To further comprehend present research status and trends, the review concentrates on CAR-T technologies, applications, adverse effects and safety measures about CAR-T cell therapy in hematological neoplasms. We believe that CAR-T cell therapy will exhibit superior safety and efficacy in the future and have potential to be a mainstream therapeutic choice for the elimination of hematologic tumor.

Keywords: CAR-T cells therapy, hematological malignancies, safety strategies

Citation styles

APA

Han, D., Xu, Z., Zhuang, Y., Ye, Z., Qian, Q. (2021). Current Progress in CAR-T Cell Therapy for Hematological Malignancies. Journal of Cancer, 12(2), 326-334. https://doi.org/10.7150/jca.48976.

ACS

Han, D.; Xu, Z.; Zhuang, Y.; Ye, Z.; Qian, Q. Current Progress in CAR-T Cell Therapy for Hematological Malignancies. J. Cancer 2021, 12 (2), 326-334. DOI: 10.7150/jca.48976.

NLM

Han D, Xu Z, Zhuang Y, Ye Z, Qian Q. Current Progress in CAR-T Cell Therapy for Hematological Malignancies. J Cancer 2021; 12(2):326-334. doi:10.7150/jca.48976. https://www.jcancer.org/v12p0326.htm

CSE

Han D, Xu Z, Zhuang Y, Ye Z, Qian Q. 2021. Current Progress in CAR-T Cell Therapy for Hematological Malignancies. J Cancer. 12(2):326-334.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.